Belgium· BE-AMP-SAM599164-00
Padcev 20 mg
A enfortumab vedotin product containing enfortumab vedotin, registered in Belgium by Astellas Pharma Europe. The same ATC class is registered in 13 of our 19 countries.
Checked against FAMHP / AFMPS (Belgium) on
Informational only — not a medical device.
Where it is registered
Enfortumab vedotin is registered in 13 of 19 countries.
Countries holding a registration under ATC L01FX13 (enfortumab vedotin), each read from that country’s own register.
- This record: Belgium, from FAMHP / AFMPS (Belgium)
- 8 of them publish a price we can compare per daily dose
Enfortumab vedotin · ATC L01FX13
13 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Ireland
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
The record
At a glance
FAMHP / AFMPS (Belgium)- Active substance
- Enfortumab Vedotin
- Manufacturer
- Astellas Pharma Europe
- Country
- Belgium (BE)
- ATC code
- L01FX13
- ATC class
- Enfortumab vedotin
- Defined daily dose
- 9.4 mg, P
- Reimbursed
- Not published by this register
- Source register
- FAMHP / AFMPS (Belgium)
- Last checked
- September 26, 2026
Packs & prices · 2
- be_apb4566196
- be_apb7737240
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
190 interactions on record for enfortumab vedotin.
Graded by severity as the source publishes them — 37 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Enfortumab vedotin · interactions on record
190 records
- 37 severe
- 150 moderate
- 3 minor
Most severe, free to view
- KetoconazoleH02CA03severe
- ClarithromycinJ01FA09severe
- KetoconazoleJ02AB02severe
- Darunavir and cobicistatJ05AR14severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Enfortumab vedotin in 15 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- FinlandPadcevAbacus Medicine A/S
- SpainPADCEV 20 MG POLVO PARA CONCENTRADO PARA SOLUCION PARA PERFUSIONAstellas Pharma Europe B.V.
- United KingdomPadcev 20mg powder for concentrate for solution for infusion vialsAstellas Pharma Ltd
- IrelandPadcev 20 mg Powder for concentrate for solution for infusionAstellas Pharma Europe B.V.
- IcelandPadcevAstellas Pharma Europe B.V.
- NorwayPadcevAstellas Pharma Europe B.V. - Leiden
- PolandPadcevAstellas Pharma Europe B.V.
- SwitzerlandPadcev 20 mg, Pulver für ein Konzentrat zur Herstellung einer InfusionslösungAstellas Pharma AG
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Padcev
- Liechtenstein · Padcev
- Norway · Padcev
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FAMHP / AFMPS (Belgium). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/17fcd731-cd67-4c5c-af1b-abb3d585aa5e GET /v1/drugs/17fcd731-cd67-4c5c-af1b-abb3d585aa5e?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Powder for concentrate for solution for infusion",
"source": "afmps",
"status": "AUTHORIZED",
"name_en": "Padcev 20 mg",
"name_fr": "Padcev 20 mg",
"name_nl": "Padcev 20 mg",
"amp_code": "SAM599164-00",
"strengths": [
"20.0000"
],
"pack_count": 1,
"substances": [
"Enfortumab Vedotin",
"Polysorbate 20"
],
"medicine_type": "ALLOPATHIC",
"atc_description": "Enfortumab Vedotin",
"authorisation_numbers": [
"EU/1/21/1615/001"
]
}See everything about enfortumab vedotin.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.